Potentially Inappropriate Prescriptions of Antipsychotic and Anticholinergic Drugs in Patients With Parkinson’s Disease

Abstract

Aim: The objective was to determine the prevalence of the potentially inappropriate antipsychotics and anticholinergics used in patients with Parkinson's disease. Materials & methods: A cross-sectional study identified the prescription of antipsychotics, anticholinergics and drugs for the treatment of Parkinson's disease. The anticholinergic burden was evaluated, and quetiapine and clozapine were considered to be adequate antipsychotics. Results: 2965 patients with Parkinson's disease were identified. The presence of psychiatric disorders and other neurological pathologies was associated with a greater probability of receiving potentially inappropriate antipsychotic prescriptions. The presence of greater number of comorbidities was associated with a greater probability of receiving anticholinergics. Conclusion: Older age and associated comorbidities, especially psychiatric and neurological comorbidities, increase the likelihood of patients with Parkinson's disease being prescribed antipsychotics and anticholinergics.

Indication-prescription study for the management of conjunctivitis in a Colombian population

“…For example, the use of polymyxin B with trimethoprim predominated in the USA (53.4%) [15], whereas it was prescribed with fusidic acid in the Netherlands (69.0%) [17], levofloxacin in China (71.8%) [21], chloramphenicol in Australia (50.8%) [16], moxifloxacin in India (52.0-53.5%) [23,24] and tobramycin in Spain (66.1%) [22] and Belgium (23.4%) [7]. The differences in drug prescription patterns have been shown in other pharmacoepidemiological studies in the country, but in different clinical contexts [25][26][27]. These variations can be explained by the epidemiological heterogeneity among countries in terms of the etiology and resistance patterns of microorganisms, the characteristics of health systems, the accessibility and availability of drugs and the marketing strategies of the pharmaceutical industry [25,26].…”